Ventyx Biosciences Analyst Ratings
Ventyx Biosciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/10/2023 | 110.97% | Evercore ISI Group | $43 → $5 | Downgrades | Outperform → In-Line |
11/07/2023 | 153.16% | Morgan Stanley | $46 → $6 | Downgrades | Overweight → Equal-Weight |
11/07/2023 | 153.16% | Stifel | → $6 | Downgrades | Buy → Hold |
11/07/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
10/10/2023 | 2262.87% | Stifel | → $56 | Reiterates | Buy → Buy |
10/10/2023 | 2094.09% | HC Wainwright & Co. | → $52 | Reiterates | Buy → Buy |
08/29/2023 | 1840.93% | Morgan Stanley | $45 → $46 | Maintains | Overweight |
08/11/2023 | 2516.03% | Credit Suisse | $63 → $62 | Maintains | Outperform |
08/11/2023 | 2094.09% | HC Wainwright & Co. | $54 → $52 | Maintains | Buy |
07/05/2023 | 2516.03% | Oppenheimer | $62 → $62 | Reiterates | Outperform → Outperform |
07/05/2023 | 2178.48% | HC Wainwright & Co. | $54 → $54 | Reiterates | Buy → Buy |
06/14/2023 | 2558.23% | Credit Suisse | → $63 | Assumes | → Outperform |
05/12/2023 | 2178.48% | HC Wainwright & Co. | → $54 | Reiterates | Buy → Buy |
03/24/2023 | 2558.23% | Credit Suisse | → $63 | Reiterates | → Outperform |
03/24/2023 | 2516.03% | Oppenheimer | $65 → $62 | Maintains | Outperform |
03/21/2023 | 3148.95% | Wells Fargo | → $77 | Initiates Coverage On | → Overweight |
03/20/2023 | 2009.7% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
01/31/2023 | 2178.48% | Canaccord Genuity | $35 → $54 | Maintains | Buy |
01/27/2023 | 2431.65% | Oppenheimer | $55 → $60 | Maintains | Outperform |
12/19/2022 | 2009.7% | Goldman Sachs | → $50 | Initiates Coverage On | → Buy |
11/17/2022 | 1798.73% | Morgan Stanley | → $45 | Initiates Coverage On | → Overweight |
09/16/2022 | 2136.29% | Stifel | $45 → $53 | Maintains | Buy |
09/13/2022 | 2009.7% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
09/12/2022 | 2642.62% | Oppenheimer | $40 → $65 | Maintains | Outperform |
09/07/2022 | 1798.73% | Stifel | → $45 | Initiates Coverage On | → Buy |
09/01/2022 | 1418.99% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
08/17/2022 | 1376.79% | Canaccord Genuity | $30 → $35 | Maintains | Buy |
08/16/2022 | 2558.23% | Credit Suisse | $53 → $63 | Maintains | Outperform |
08/16/2022 | 1587.76% | Oppenheimer | $30 → $40 | Maintains | Outperform |
05/09/2022 | 2136.29% | Credit Suisse | → $53 | Initiates Coverage On | → Outperform |
03/31/2022 | 1165.82% | Canaccord Genuity | → $30 | Initiates Coverage On | → Buy |
02/01/2022 | 1165.82% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
11/15/2021 | 2009.7% | Evercore ISI Group | → $50 | Initiates Coverage On | → Outperform |
11/15/2021 | 1165.82% | Jefferies | → $30 | Initiates Coverage On | → Buy |
11/15/2021 | 2009.7% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/10/2023 | 110.97% | Evercore ISI 集团 | 43 美元 → 5 美元 | 降级 | 跑赢大盘 → 在线 |
11/07/2023 | 153.16% | 摩根士丹利 | 46 美元 → 6 美元 | 降级 | 超重 → 重量相等 |
11/07/2023 | 153.16% | Stifel | → 6 美元 | 降级 | 买入 → 持有 |
11/07/2023 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
2023 年 10 月 10 日 | 2262.87% | Stifel | → 56 美元 | 重申 | 购买 → 购买 |
2023 年 10 月 10 日 | 2094.09% | HC Wainwright & Co. | → 52 美元 | 重申 | 购买 → 购买 |
08/29/2023 | 1840.93% | 摩根士丹利 | 45 美元 → 46 美元 | 维护 | 超重 |
08/11/2023 | 2516.03% | 瑞士信贷 | 63 美元 → 62 美元 | 维护 | 跑赢大盘 |
08/11/2023 | 2094.09% | HC Wainwright & Co. | 54 美元 → 52 美元 | 维护 | 买 |
07/05/2023 | 2516.03% | 奥本海默 | 62 美元 → 62 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
07/05/2023 | 2178.48% | HC Wainwright & Co. | 54 美元 → 54 美元 | 重申 | 购买 → 购买 |
06/14/2023 | 2558.23% | 瑞士信贷 | → 63 美元 | 假设 | → 跑赢大盘 |
05/12/2023 | 2178.48% | HC Wainwright & Co. | → 54 美元 | 重申 | 购买 → 购买 |
2023 年 3 月 24 日 | 2558.23% | 瑞士信贷 | → 63 美元 | 重申 | → 跑赢大盘 |
2023 年 3 月 24 日 | 2516.03% | 奥本海默 | 65 美元 → 62 美元 | 维护 | 跑赢大盘 |
03/21/2023 | 3148.95% | 富国银行 | → 77 美元 | 启动覆盖范围开启 | → 超重 |
03/20/2023 | 2009.7% | HC Wainwright & Co. | → 50 美元 | 重申 | → 购买 |
01/31/2023 | 2178.48% | Canaccord Genu | 35 美元 → 54 美元 | 维护 | 买 |
01/27/2023 | 2431.65% | 奥本海默 | 55 美元 → 60 美元 | 维护 | 跑赢大盘 |
2022 年 12 月 19 日 | 2009.7% | 高盛 | → 50 美元 | 启动覆盖范围开启 | → 购买 |
11/17/2022 | 1798.73% | 摩根士丹利 | → 45 美元 | 启动覆盖范围开启 | → 超重 |
2022 年 9 月 16 日 | 2136.29% | Stifel | 45 美元 → 53 美元 | 维护 | 买 |
09/13/2022 | 2009.7% | HC Wainwright & Co. | 36 美元 → 50 美元 | 维护 | 买 |
09/12/2022 | 2642.62% | 奥本海默 | 40 美元 → 65 美元 | 维护 | 跑赢大盘 |
09/07/2022 | 1798.73% | Stifel | → 45 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 1 月 9 日 | 1418.99% | HC Wainwright & Co. | → 36 美元 | 启动覆盖范围开启 | → 购买 |
08/17/2022 | 1376.79% | Canaccord Genu | 30 美元 → 35 美元 | 维护 | 买 |
08/16/2022 | 2558.23% | 瑞士信贷 | 53 美元 → 63 美元 | 维护 | 跑赢大盘 |
08/16/2022 | 1587.76% | 奥本海默 | 30 美元 → 40 美元 | 维护 | 跑赢大盘 |
05/09/2022 | 2136.29% | 瑞士信贷 | → 53 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
03/31/2022 | 1165.82% | Canaccord Genu | → 30 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 1 月 2 日 | 1165.82% | 奥本海默 | → 30 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
11/15/2021 | 2009.7% | Evercore ISI 集团 | → 50 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
11/15/2021 | 1165.82% | 杰富瑞集团 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
11/15/2021 | 2009.7% | 派珀·桑德勒 | → 50 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Ventyx Biosciences (VTYX)?
Ventyx Biosciences(VTYX)的目标价格是多少?
The latest price target for Ventyx Biosciences (NASDAQ: VTYX) was reported by Evercore ISI Group on November 10, 2023. The analyst firm set a price target for $5.00 expecting VTYX to rise to within 12 months (a possible 110.97% upside). 21 analyst firms have reported ratings in the last year.
Evercore ISI集团于2023年11月10日公布了Ventyx Biosciences(纳斯达克股票代码:VTYX)的最新目标股价。该分析公司将目标股价定为5.00美元,预计VTYX将在12个月内升至12个月内(可能上涨110.97%)。去年有21家分析公司公布了评级。
What is the most recent analyst rating for Ventyx Biosciences (VTYX)?
Ventyx Biosciences(VTYX)的最新分析师评级是多少?
The latest analyst rating for Ventyx Biosciences (NASDAQ: VTYX) was provided by Evercore ISI Group, and Ventyx Biosciences downgraded their in-line rating.
Evercore ISI集团对Ventyx Biosciences(纳斯达克股票代码:VTYX)的最新分析师评级由Evercore ISI集团提供,Ventyx Biosciences下调了其在线评级。
When is the next analyst rating going to be posted or updated for Ventyx Biosciences (VTYX)?
Ventyx Biosciences(VTYX)的下一份分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Ventyx Biosciences的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Ventyx Biosciences的最新评级是在2023年11月10日公布的,因此您应该预计下一个评级将在2024年11月10日左右公布。
Is the Analyst Rating Ventyx Biosciences (VTYX) correct?
分析师对Ventyx Biosciences(VTYX)的评级是否正确?
While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a downgraded with a price target of $43.00 to $5.00. The current price Ventyx Biosciences (VTYX) is trading at is $2.37, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Ventyx Biosciences(VTYX)评级已下调,目标股价为43.00美元至5.00美元。Ventyx Biosciences(VTYX)目前的交易价格为2.37美元,超出了分析师的预期区间。